AstraZeneca stock at GBP 125.52 on September 25, 2026
Published on 09/28/2026 at 08:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ahead of the next regular London trading session, AstraZeneca PLC shares had closed at GBP 125.52 on September 25, 2026, a daily increase of 1.23 percent on the London Stock Exchange.
Reference session
The September 25 close was the latest reported regular-session price for AstraZeneca’s London-listed ordinary shares. The stock had closed at GBP 124.00 on September 24, according to historical market data.
Recent company developments
In a release published September 25, AstraZeneca said the US Food and Drug Administration had accepted and granted Priority Review to its supplemental Biologics License Application for Imfinzi in combination with enfortumab vedotin for certain patients with muscle-invasive bladder cancer. The company said the FDA decision date is anticipated in the fourth quarter of 2026.
AstraZeneca said the application was based on interim results from the VOLGA Phase III trial, which showed statistically significant and clinically meaningful improvements in event-free survival and overall survival versus the comparator. The company also said regulatory applications based on VOLGA were under review in the European Union, Japan and other countries.
Young Health Programme expands
In a separate September 23 release, AstraZeneca announced a new five-year phase of its Young Health Programme with UNICEF and other partners. The company said its investment in the programme had exceeded USD 100 million since 2010 and that the next phase aims to reach an additional 10 million young people and train 800,000 youth advocates by 2030.
